Dosage form design for improvement of bioavailability of levodopa VI: formulation of effervescent enteric-coated tablets.
A new dosage form of levodopa, which has the characteristics of loading high concentrations of levodopa at the upper part of the intestine, has been developed to improve its bioavailability. It is shown that an effervescent tablet formulation, coated with hydroxypropyl methylcellulose phthalate (carboxybenzoyl radical content: 20-24%) as the enteric material, is suitable for the purpose of dissolution. This was confirmed from animal experiments, which showed that tablets of this composition disintegrate instantly on reaching the upper part of the intestine. This tablet was considered appropriate for the bioavailability tests described in this paper.
D000818:Animals; D001639:Bicarbonates; D001682:Biological Availability; D004285:Dogs; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption; D007700:Kinetics; D007980:Levodopa / Q000008:administration & dosage* / Q000378:metabolism; D008297:Male; D017693:Sodium Bicarbonate; D012995:Solubility; D013608:Tablets, Enteric-Coated
D001639:Bicarbonates; D013608:Tablets, Enteric-Coated; D007980:Levodopa; D017693:Sodium Bicarbonate